Insights

Gathering insights about Akero Therapeutics…

Similar companies to Akero Therapeutics

Akero Therapeutics Tech Stack

Akero Therapeutics uses 8 technology products and services including Shopify, ADP HRMS, ADP, and more. Explore Akero Therapeutics's tech stack below.

Shopify
E-commerce
ADP HRMS
Human Resource Management System
ADP
Human Resource Management System
Microsoft
Miscellaneous
Acquia Cloud Platform
Platform As A Service
PHP
Programming Languages
Cloudflare Bot Management
Security
Google Tag Manager
Tag Management

Media & News

Akero Therapeutics's Email Address Formats

Akero Therapeutics uses at least 1 format(s):

Akero Therapeutics Email Formats	Example	Percentage
First@akerotx.com	John@akerotx.com	34%
Last@akerotx.com	Doe@akerotx.com	16%
FLast@akerotx.com	JDoe@akerotx.com	16%
First@akerotx.com	John@akerotx.com	34%

Frequently Asked Questions

Where is Akero Therapeutics's headquarters located?

Akero Therapeutics's main headquarters is located at 601 Gateway Blvd Suite 350 South San Francisco, California 94080 US. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Akero Therapeutics's phone number?

You can contact Akero Therapeutics's main corporate office by phone at

+1-650-487-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Akero Therapeutics's stock symbol?

Akero Therapeutics is a publicly traded company; the company's stock symbol is AKRO.

What is Akero Therapeutics's official website and social media links?

Akero Therapeutics's official website is akerotx.com and has social profiles on LinkedIn.

How much revenue does Akero Therapeutics generate?

As of August 2024, Akero Therapeutics's annual revenue reached $7.5M.

What is Akero Therapeutics's SIC code NAICS code?

Akero Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Akero Therapeutics have currently?

As of August 2024, Akero Therapeutics has approximately 64 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Operating Officer: D. S.Chief Scientific Officer: T. R.Vice President Of Quality Assurance: D. V.. Explore Akero Therapeutics's employee directory with LeadIQ.

What industry does Akero Therapeutics belong to?

Akero Therapeutics operates in the Biotechnology Research industry.

What technology does Akero Therapeutics use?

Akero Therapeutics's tech stack includes ShopifyADP HRMSADPMicrosoftAcquia Cloud PlatformPHPCloudflare Bot ManagementGoogle Tag Manager.

What is Akero Therapeutics's email format?

Akero Therapeutics's email format typically follows the pattern of . Find more Akero Therapeutics email formats with LeadIQ.

How much funding has Akero Therapeutics raised to date?

As of August 2024, Akero Therapeutics has raised $367M in funding. The last funding round occurred on Mar 05, 2024 for $367M.

When was Akero Therapeutics founded?

Akero Therapeutics was founded in 2017.

Akero Therapeutics

Biotechnology ResearchCalifornia, United States51-200 Employees

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH. Akero is headquartered in South San Francisco.

Company Overview

Headquarters: 601 Gateway Blvd Suite 350 South San Francisco, California 94080 US
Phone number: ✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-650-487-****
Website: akerotx.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: AKRO
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2017
Employees: 51-200

Media & News

Funding & Financials

$367M
Akero Therapeutics has raised a total of $367M of funding over 7 rounds. Their latest funding round was raised on Mar 05, 2024 in the amount of $367M.
$10M
Akero Therapeutics's revenue is in the range of $10M

Funding & Financials

$367M
Akero Therapeutics has raised a total of $367M of funding over 7 rounds. Their latest funding round was raised on Mar 05, 2024 in the amount of $367M.
$10M
Akero Therapeutics's revenue is in the range of $10M

Company Leadership

D. S.
Chief Operating Officer
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
T. R.
Chief Scientific Officer
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. V.
Vice President Of Quality Assurance
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. Y.
Executive Vice President And Coo
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
K. Y.
Evp And Chief Development Officer
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

T. R.
Chief Scientific Officer
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
R. S.
Vice President, Clinical Research And Medical Affairs
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
Y. R.
Vp, Fp&a
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. B.
Vice President
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
D. V.
Vice President Of Quality Assurance
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Akero Therapeutics and Millions of Other Companies
Sign up for full access to Akero Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Akero Therapeutics

Sarepta Therapeutics

Arbutus Biopharma Corporation

Alnylam Pharmaceuticals

Akero Therapeutics Tech Stack

Media & News

Akero Therapeutics, Inc. had issues with substantial losses have opportunity to lead Class Action lawsuit - AKRO on Jun 25th '24.

Akero Therapeutics, Inc. had issues with Securities Class Action - AKRO on Jun 25th '24.

Akero Therapeutics, Inc. had issues with potential violations of the federal securities laws on Mar 20th '24.

Akero Therapeutics, Inc. is developing EFX, Akero's lead product candidate.

Akero Therapeutics, Inc. is developing transformational medicines for patients with serious metabolic diseases.

Akero Therapeutics, Inc. has issues with Class Action lawsuit - Hagens Berman.

Akero Therapeutics, Inc. launched Phase 2b SYMMETRY study on Oct 10th '23.

Akero Therapeutics's Email Address Formats

Frequently Asked Questions

Where is Akero Therapeutics's headquarters located?

What is Akero Therapeutics's phone number?

What is Akero Therapeutics's stock symbol?

What is Akero Therapeutics's official website and social media links?

How much revenue does Akero Therapeutics generate?

What is Akero Therapeutics's SIC code NAICS code?

How many employees does Akero Therapeutics have currently?

What industry does Akero Therapeutics belong to?

What technology does Akero Therapeutics use?

What is Akero Therapeutics's email format?

How much funding has Akero Therapeutics raised to date?

When was Akero Therapeutics founded?

Akero Therapeutics

Company Overview

Media & News

Akero Therapeutics, Inc. had issues with substantial losses have opportunity to lead Class Action lawsuit - AKRO on Jun 25th '24.

Akero Therapeutics, Inc. had issues with Securities Class Action - AKRO on Jun 25th '24.

Akero Therapeutics, Inc. had issues with potential violations of the federal securities laws on Mar 20th '24.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?